| |
Treatment of Established Recurrent Hepatitis C in Liver
Transplant Recipients with Pegylated Interferon Alfa-2b and Ribavirin
Therapy
The
management issues of transplant patients with hepatitis C virus (HCV) are
complex, and interferon therapy is often ineffective. The current study
offers data from a retrospective review in
liver-transplant recipients
suffering from
HCV recurrence
that were treated with
pegylated alfa-2b interferon (Peg Intron) and
ribavirin.
The study
was a retrospective review of transplant recipients that received
combination pegylated alfa-2b interferon (1.5 mcg/kg/wk) and ribavirin
(400-600 mg/day) therapy intended for at least 48 weeks.
Complications were recorded and included
neutropenia
(<750
cells),
anemia
(hemoglobin <8 g) with and without treatment consisting of blood
transfusions,
erythropoietin,
or dose reduction of
ribavirin,
and
depression.
The
diagnosis of HCV recurrence was determined by an increase in liver
chemistries, histopathologic findings with inflammation along with viral
recurrence using the
COBAS AMPLICOR HCV test.
Results
Fifty-seven
liver-transplant recipients were included, 29 naive (group 1) to therapy and
28
nonresponders
(group 2) to at least 6 months of interferon and ribavirin therapy.
Eight
(27.6%) patients in group 1 and six (21%) patients in group 2 were HCV
nondetectable at the end of 48 weeks of therapy.
Ribavirin
therapy was decreased in 13 of 29 (45%) for group 1 and 11 of 28 (39%) in
group 2.
Therapeutic
interventions were 4 of 57 (7%) blood transfusions, 23 of 57 (40%)
erythropoietin, and 17 of 57 (30%) filgrastim.
Conclusion
The authors
conclude, “Combination
pegylated interferon with ribavirin
appears to [be an] effective therapy in
HCV recurrence
and in HCV nonresponsive to interferon and ribavirin.”
“This data
reveals the difficulty and caution that must be taken when treating HCV-R
liver-transplant recipients with combination pegylated alfa-2b interferon
and ribavirin therapy.”
Center
for Liver Diseases, Division of GI Transplant, Department of Medicine,
University of Miami, Miami, FL, USA.
01/14/05
Reference
G W Neff and others. Treatment of established recurrent hepatitis C in
liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin
therapy. Transplantation 78(9):1303-7. November 15, 2004.
Link to Index to All Hepatitis C Articles - A to Z
http://www.hivandhepatitis.com/hep_c/news/2005/011405_a.html
Doctors in Germany are touting the benefits of performing
transplants for children with liver disease.1 Since beginning
its liver transplant program in 1989, University Hospital Eppendorf at the
University of Hamburg has seen "near perfect" patient survival, writes a
group of hepatologists led by Dieter Broering, MD, in the department of
Hepatobiliary Surgery at the hospital.
Transplant is the Standard Therapy
Approach
In this country,
liver transplantation is the standard of
care for children with
end-stage liver disease; that is, the
point at which their
liver can no longer effectively be
treated with medication. Symptoms of end-stage liver disease include
fatigue, jaundice, impaired blood clotting, muscle wasting, hepatic
encephalopathy, and
portal hypertension. It's estimated that
each year, 800 children are placed on the liver transplant waiting list.2
When liver transplants are considered for
children, there are several types that
can be performed. Split-liver transplantation involves dividing a
cadaver's liver while it is still in the donor's body with blood flowing
to it. This is aimed at increasing the number of available livers since
liver tissue can regrow. Living-related donor transplants involve a
portion of an adult relative's liver that is transplanted to a child
recipient. In reduced-liver transplant, surgeons take a portion of a
cadaver's liver and place it in a child. These help compensate for
dramatic differences in patient and donor weight. Finally, whole-liver
transplants involve the removal of an entire, healthy donor liver. But the
shortage of whole pediatric livers has forced doctors to develop more
innovative methods of liver transplantation.2
In a paper published in the journal Annals of
Surgery in December, Broering and his team analyzed the outcomes of
pediatric liver transplant procedures performed at their institution
between 2001 and 2003. In all, 132 liver transplants were performed for
children during that time.
"Of 132 consecutive pediatric liver transplants, no
patients died within the 6 months post-transplantation," Broering's group
noted. During extended follow-up, 3 patients died, one due to severe
pneumonia, and the second due to an unknown cause. Both had healthy livers
at the time of death. The third patient had a recurrence of an unknown
liver disease 9 months after undergoing transplantation.
The odds of survival of transplanted livers in these
cases was 92% 3 months after surgery. Actual survival was 86%.
Transplant Setbacks
There were some cases in which complications arose. In 12 percent of the
patients who had transplants during the 2-year period, retransplantation
was necessary due to chronic liver rejection, liver non-function or poor
function, and arterial thrombosis.
Other complications occurred rarely. Biliary
complications occurred in 6% of cases, about 8-and-a-half percent of the
patients had arterial problems, intestinal perforation was found in just 3
percent of the patients after surgery, and in 5 percent, postoperative
bleeding required doctors to perform surgery a second time. Portal vein
complications occurred in a very small proportion of patients.
"Progress during the past 15 years has enabled us to
perform pediatric liver transplantation with near perfect patient
survival," wrote Broering and his associates. This can be directly
attributed to "advances in post-transplant care of the recipients,
technical refinements, standardization of surgery and monitoring, and
adequate choice of the donor organ and transplantation technique."
A Key 'Turning Point' in Pediatric
Liver Disease
These outcomes mark a significant "turning point" in pediatric
liver transplant outcomes, the doctors point out. We are nearing the day
at which immediate survival after liver transplant "will be considered the
norm."
1. Broering DC, Kim JS, Mueller T et al. One hundred
thirty-two consecutive pediatric liver transplants without hospital
mortality: lessons learned and outlook for the future. Ann Surg
2004 Dec;240(6):1002-12.
2. Types of Liver Transplant. Texas Children's Hospital. Available at:
http://www.texaschildrenshospital.org/Parents/TipsArticles/ArticleDisplay.aspx?aid=773.
Accessed January 5, 2005.
John Martin is a long-time health journalist and an
editor for Priority Healthcare. His credits include coverage of health
news for the website of Fox Television's The Health Network, and articles
for the New York Post and other consumer and trade publications.
http://www.hepatitisneighborhood.com/content/in_the_news/archive_2203.aspx
| Law & Organs - By: Geoff
Drushel |
Back |
| Summary: |
|
Directed organ
donation is legal, but is it right? |
| |
| Story: |
|
Spurred on by a
Houston man’s successful quest to obtain a new liver via billboard and
internet advertising, as well as similar efforts by others that quickly
followed, the organization that oversees organ distribution in the
United States is pushing hard for a change – one it says is desperately
needed to stem a rising tide of private organ solicitation that
threatens to erode a delicate system.
The case of Todd
Krampitz, a 32-year-old man who was diagnosed with severe liver cancer
in May but who received a new liver after pleading his case publicly,
prompted the United Network for Organ Sharing in November to strongly
recommend that hospitals discourage patients from soliciting organs and
to even refuse to perform such transplants. Krampitz, who purchased
billboard space along two busy freeways last summer while simultaneously
launching an effort on the internet, garnered national attention for the
unprecedented request. His message, “I need a liver. Please help save my
life!” was received, and a short time later, Krampitz received an organ
from an out-of-state family who had heard of his plight. The operation
was performed at in . Krampitz, whom doctors only months earlier had
deemed too sick for transplant, had gotten his new liver. So all’s well
that ends well, right? Not exactly.
A hue and cry
Not long after
Krampitz’s outdoor advertising campaign and cyber search got under way,
people began to question his methods. Transplant surgeons, medical
ethicists and particularly those waiting on transplant lists for UNOS-distributed
organs charged that Krampitz’s efforts threatened to undermine a
20-year-old system that had been established precisely for the purposes
of ensuring fairness among organ donors and recipients. Krampitz, they
said, had in effect cut to the front of the line, depriving someone of
an organ – someone who had followed the rules and worked within the
system despite the rather scary statistic that up to 25 percent of those
on transplant lists for livers die while waiting for their “gift of
life.” Krampitz’s wife, Julie, declined comment for this story except to
say that she prefers to focus only on organ donation and not on “any
controversy” resulting from their mission to save Todd’s life. “If
everyone would focus on the true underlying issue of increasing organ
donation awareness and drop the controversy, the story would be much
more touching and effective. What organ donation awareness lacks is
putting faces and personal stories with a need. Blood donation awareness
is done so effectively because their commercials show real people
(whose) lives were saved because someone donated blood,” Julie Krampitz
says, adding that her husband is “doing well” since his transplant.
After receiving the
organ, the Krampitzes put up a new billboard saying “Thank You” and
encouraging more people to consider organ donation. In the wake of their
successful campaign, others in need of organs followed suit, inundating
the internet with similar pleas. Meanwhile, UNOS was meeting to discuss
the solicitation of organ donations through advertising, voting nearly
unanimously in the end to condemn such efforts and calling on hospitals
and transplant surgeons not to perform those surgeries. While
nonbinding, meaning they cannot force hospitals and doctors to comply
with their wishes, the vote was praised by many in the medical
community, including ethicists who say the existing system for ranking
patients in need of organs is the best way to ensure fairness.
Jumping the line
Dr. Arthur L. Caplan,
a leading ethicist and chairman of the department of medical ethics at
the University of Pennsylvania, says directed donation of a loved one’s
organ(s) to a family member or close friend as it was intended, whether
cadaver or living, is not the problem, but, rather, that it is the
solicitation of organs from total strangers through advertising that’s
creating the outcry. “We’re basically talking about how to move organs
around among people who don’t know each other and aren’t related; that’s
where the ethics are,” Caplan says. “In cadaver donation, I think
there’s a system that already exists that works, and I think that people
should be made to follow it. They may have to toughen up the rules a bit
to force compliance, but I think that’s the way to go because,
otherwise, you’re going to wind up killing people. The organs will be
shipped around and go bad and lives will be lost.”
Caplan says he
believes Krampitz “jumped the line” when he solicited and received an
organ from a cadaver. “If he had wanted to put up a billboard and say
‘Give me one of your kidneys,’ then I can’t say that’s jumping a line
because there isn’t any type of (national) system or set of protocols
for (living donors),” Caplan says. “There are really two different
activities going on. One (involves living donors and the other) involves
people who want to designate a cadaver donation to someone in need. And
that, I think, is a terrible idea.”
He says the national
transplant network, established to oversee the distribution of organs
based on a variety of factors, including the condition and location of
the patient, was set up because hospitals of the day were sequestering
organs for use in their own patients, and people were dying as a result
because there was greater need elsewhere. The goal of UNOS, Caplan says,
was to make certain donated organs go to those patients who would most
medically benefit. “So we set up this whole system to make things fair.
That’s the whole UNOS-run allocation system, which basically pays
attention to physiological factors like blood type and tissue type and
then urgency and time spent on the waiting list and other factors that
are more medical than anything else,” he says. “If you start saying,
‘I’m going to send this cadaver donation to someone who put up a
billboard or to my fellow member of the Knights of Columbus’ or
something, the problem becomes that you have to ship these organs, and
you don’t have a lot of time to do that. You’re risking real loss of the
organ.
“And you’re also
undercutting a system that has worked very well to make sure that
everybody has an equal chance,” he adds. “So I am very, very, very
critical of anything that proposes to allow people to jump to the head
of the line in the cadaver pool. I don’t think it’s fair to the poor,
and I think it risks losing organs and is just wrong for a number of
reasons. Directed donation from cadaver sources, it seems to me, is
immoral and even lethal because you can end up killing people.” Caplan
concedes, however, that while he believes it is wrong ethically,
directed cadaver donation among strangers is not illegal, hence the
need, he believes, for binding action by UNOS and the nation’s
transplant surgeons. Directed donation among family members and those
with strong emotional ties is allowed under the Uniform Anatomical Gift
Act, federal legislation enacted in 1968 and revised in 1987 to
harmonize the organ donation laws among the 50 states. Caplan says he
has no problem with that.
A surgeon’s view
Caplan is hardly alone
in his call for action. Dr. R. Patrick Wood, a transplant surgeon at St.
Luke’s Episcopal Hospital in Houston and former board member of UNOS,
currently sits on the board of LifeGift as its southeast regional
medical director. He agrees with Caplan in that he believes what
Krampitz did and what others are doing undermines the system and is
simply “unfair” to others. “The whole premise behind directed donation
was to allow people who have an emotional relationship with the person
waiting for the transplant or their family to allow them to direct a
donation based on that personal relationship,” says Wood, who also sits
on the board of Hepatitis magazine. “It was never the intention of the
Uniform Anatomical Gift Act to provide livers to the person who has the
best advertising.”
Wood says that in the
past, a family member would direct a donation of a liver, for example,
but then their loved one’s other organs also would be harvested and used
to help other people. And it was less than 1 percent of people, he adds,
who were taking advantage of this type of organ donation. “But I think
if everyone goes out and starts to advertise, it is not in the spirit of
the concept of directed donation,” Wood says. “I think that UNOS is
going to have to put some regulations in place to either prohibit
directed donation or to limit it only to people who do have that
emotional relationship with their donor and not to somebody who has just
read about somebody’s story on the internet.
“I think if there’s
going to be a way to end-run the system, then in order to maintain
confidence in the system, we may have to put processes in place to
eliminate that loophole,” Wood says. “I also think, however, that if I
had a relative on the transplant list and one of my family members died,
it should be my right to donate to that person because I have an
emotional attachment to that person. But as far as who can advertise
best, obviously that’s not in the spirit of what we’re talking about. If
all 80,000 or so people on the waiting list all had internet sites, you
can imagine that it would be somewhat chaotic.”
In the meantime, the
80,000-plus people on waiting lists throughout the country will continue
to wait for viable organs as the debate over the system and what is fair
to everyone continues as well, swirling its way through the halls of
academia and the various medical institutions and winding up ultimately,
should a resolution not be met first, in the halls of Congress. “I would
hope that we wouldn’t have to go back to Congress and plod through the
whole system again because of all the time that would take,” Wood says.
“It needs a solution relatively quickly and, as we all know, Congress
runs at a pace where it may be several years before we get anything out
of them.” |
| http://www.hepatitismag.com/storydetail.asp?storyid=133 |
|